menu
    • menu
    [{"orgOrder":0,"company":"Genpharma","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Autologous CD34+ cell enriched HSPC","moa":"ARSA gene","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genpharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Dispersion for infusion","sponsorNew":"Genpharma \/ GenPharm","highestDevelopmentStatusID":"12","companyTruncated":"Genpharma \/ GenPharm"},{"orgOrder":0,"company":"Genpharma","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genpharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genpharma \/ Genpharm","highestDevelopmentStatusID":"12","companyTruncated":"Genpharma \/ Genpharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Genpharma

    Menu

    Genpharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genpharma

                            Morocco arrow
                            CPhI India 2024
                            Not Confirmed

                            Genpharma

                            Morocco arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Odevixibat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Albireo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf R...

                            Details : The agreement with Genpharm advances Albireo’s global strategy for the commercialization of Bylvay in a key region following European and U.S. regulatory approvals of the use of Bylvay in patients with PFIC based on the PEDFIC study.

                            Brand Name : Bylvay

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 18, 2021

                            Lead Product(s) : Odevixibat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Albireo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genpharma

                            Morocco arrow
                            CPhI India 2024
                            Not Confirmed

                            Genpharma

                            Morocco arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous CD34+ cell enriched HSPC

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Orchard Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East...

                            Details : Under terms of the agreements, GenPharm and GEN will be responsible for all activities related to identifying patients, driving disease awareness, and ensuring market access for Libmeldy in their respective territories.

                            Brand Name : Libmeldy

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 19, 2021

                            Lead Product(s) : Autologous CD34+ cell enriched HSPC

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Orchard Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth